Interim Guidance for the use of Tocilizumab in the Management of Patients who have Severe COVID-19 with Suspected Hyperinflammation [v5.0]

This document is intended for use by healthcare professionals only. This guidance is specific to the management of Patients with confirmed Severe COVID-19 with Suspected Hyperinflammation. While the guidance is intended to strengthen clinical management of these patients it does not replace clinical judgment or specialist consultation. This guidance should be read in conjunction with the National HSE Infection Prevention and Control (IPC) Guidance for Possible or Confirmed COVID-19 .